Amgen Manufacturing, Limited

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)

Phase 1

Completed

Conditions: Elevated Serum Lipoprotein(a)

Interventions: Drug: Olpasiran

First Posted Date: 2021-08-03

Last Posted Date: 2025-02-10

Lead Sponsor: Amgen

Target Recruit Count: 24

Registration Number: NCT04987320

Locations: 🇭🇰
Queen Mary Hospital, Hong Kong, HK, Hong Kong

Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Phase 2

Terminated

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: Efavaleukin alfa

First Posted Date: 2021-08-03

Last Posted Date: 2024-11-25

Lead Sponsor: Amgen

Target Recruit Count: 224

Registration Number: NCT04987307

Locations: 🇺🇸
Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
🇺🇸
Birmingham Digestive Health Research, LLC, Homewood, Alabama, United States
🇺🇸
Arizona Health Research, Mesa, Arizona, United States

and more 197 locations

Study of VIB7734 for the Treatment of Moderate to Severely Active SLE

Phase 2

Completed

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: VIB7734
Other: Placebo

First Posted Date: 2021-06-14

Last Posted Date: 2024-07-23

Lead Sponsor: Amgen

Target Recruit Count: 214

Registration Number: NCT04925934

Locations: 🇺🇸
Millennium Research, Ormond Beach, Florida, United States
🇺🇸
Inland Rheumatology Clinical Trials Incorporated, Upland, California, United States
🇺🇸
Clinical Research of West Florida Inc - Clearwater, Clearwater, Florida, United States

and more 64 locations

A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Phase 2

Terminated

Conditions: Sclerosis, Systemic
Diffuse Cutaneous Systemic Sclerosis

Interventions: Drug: Placebo
Drug: HZN-825 BID
Drug: HZN-825 QD

First Posted Date: 2021-03-04

Last Posted Date: 2025-03-06

Lead Sponsor: Amgen

Target Recruit Count: 300

Registration Number: NCT04781543

Locations: 🇷🇸
Institute of Rheumatology - PPDS, Belgrade, Serbia
🇷🇸
Military Medical Academy, Belgrade, Serbia
🇷🇸
Institute for Treatment and Rehabilitation Niska Banja, Niška Banja, Serbia

and more 1 locations

A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)

Phase 4

Completed

Conditions: Uncontrolled Gout
Chronic Gout

Interventions: Biological: Pegloticase
Drug: Methotrexate (MTX)

First Posted Date: 2021-02-21

Last Posted Date: 2024-10-09

Lead Sponsor: Amgen

Target Recruit Count: 50

Registration Number: NCT04762498

Locations: 🇺🇸
ProHealth Research Center, Doral, Florida, United States
🇺🇸
Biopharma Informatic, LLC, Houston, Texas, United States
🇺🇸
Napa Research Center, Pompano Beach, Florida, United States

and more 9 locations

Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta

Phase 1

Completed

Conditions: Osteogenesis Imperfecta

Interventions: Drug: Romosozumab
Dietary Supplement: Calcium
Dietary Supplement: Vitamin D

First Posted Date: 2020-09-11

Last Posted Date: 2024-04-15

Lead Sponsor: Amgen

Target Recruit Count: 25

Registration Number: NCT04545554

Locations: 🇬🇷
General Children Hospital Panagioti and Aglaias Kyriakou, Athens, Greece
🇮🇹
IRCCS Ospedale Pediatrico Bambino Gesu, Roma, Italy
🇹🇷
Koc Universitesi Hastanesi, Istanbul, Turkey

and more 12 locations

Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease

Phase 3

Recruiting

Conditions: Behçet Disease

Interventions: Drug: Apremilast
Drug: Placebo

First Posted Date: 2020-08-27

Last Posted Date: 2024-11-18

Lead Sponsor: Amgen

Target Recruit Count: 60

Registration Number: NCT04528082

Locations: 🇬🇷
General Hospital of Thessaloniki Ippokrateio, Thessaloniki, Greece
🇫🇷
Hospices Civils de Lyon Hopital Femme Mere Enfant, Bron cedex, France
🇫🇷
Hopital Necker Enfants Malades, Paris, France

and more 24 locations

Myasthenia Gravis Inebilizumab Trial

Phase 3

Active, not recruiting

Conditions: Myasthenia Gravis

Interventions: Drug: IV Placebo
Drug: inebilizumab

First Posted Date: 2020-08-24

Last Posted Date: 2025-02-20

Lead Sponsor: Amgen

Target Recruit Count: 238

Registration Number: NCT04524273

Locations: 🇺🇸
Viela Bio Investigative Site - 1015, Orange, California, United States
🇺🇸
Viela Bio Investigative Site - 1002, New Haven, Connecticut, United States
🇺🇸
Viela Bio Investigative Center - 1024, Washington, District of Columbia, United States

and more 101 locations

Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

Phase 4

Completed

Conditions: Gout
Uncontrolled Gout
Chronic Uncontrolled Gout

Interventions: Biological: Pegloticase with MTX

First Posted Date: 2020-08-13

Last Posted Date: 2025-01-07

Lead Sponsor: Amgen

Target Recruit Count: 191

Registration Number: NCT04511702

Locations: 🇺🇸
Orthopedic Physicians Alaska, Anchorage, Alaska, United States
🇺🇸
D&H Tamarac Research Centers, Tamarac, Florida, United States
🇺🇸
Arthritis & Rheumatology Research, Mesa, Arizona, United States

and more 33 locations

A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

Phase 3

Withdrawn

Conditions: Non-squamous NSCLC
Metastatic Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: ABP 215
Drug: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2020-07-10

Last Posted Date: 2023-07-03

Lead Sponsor: Amgen

Registration Number: NCT04466917

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy